We are investigating Oasmia Pharmaceutical AB (OASM) (“Oasmia” or the “Company”) for potential violations of the federal securities laws.
On July 9, 2019, post-market, Oasmia reported that it had terminated its “engagement and cooperation” with former executive chairman Julian Aleksov without further pay, following a tax audit that revealed missing funds connected to suspicious transactions between Oasmia and companies controlled by Aleksov and his former father-in-law. On this news, Oasmia’s American depositary receipt price fell $0.34 per share, or 13.08%, to close at $2.26 per share on July 10, 2019.